Happy New Year PDCD Community!

We are so proud to share with you all our 2023 Annual Report. We hope you take some time to review this important document over the next few days. It includes our mission statement, vision, core values, board of directors, financials for tax year 2023, highlights of what we accomplished in 2023 and a snapshot of where we are headed in 2024. 2023 was a year of tremendous growth and collaboration for Hope for PDCD. Together, we achieved many milestones that will bring us closer to a cure for PDCD. Read the 2023 Annual Report

🧬 Hope for PDCD Foundation, along with Cure MITO Foundation and more, has joined the Critical Path Institute (C-Path)’s task force focused on accelerating drug development for mitochondrial and inherited metabolic diseases. The task force will lay the groundwork for specific solutions, offering valuable insights that aim to contribute to regulatory decision-making.

WHAT IS C-PATH?

Critical Path Institute (C-Path) is an independent, nonprofit organization established in 2005 as a public and private partnership. C-Path’s mission is to catalyze the development of new approaches that advance medical innovation and regulatory science, accelerating the path to a healthier world. 

WHY PARTNER WITH C-PATH?

C-Path’s demonstrated expertise will be leveraged to ensure success, specifically its track record in generating tangible solutions that have accelerated drug development in rare and pediatric indications, utilizing the power of C-Path's Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP®) to integrate multiple patient-level data sources. This collaborative task force will provide a neutral environment for industry, regulatory agencies, academia, and the patient community to collaborate and actively contribute to advancing solutions aimed at facilitating therapeutic developments for these communities.

WHAT OTHERS ARE SAYING:

“Uniting stakeholders through a neutral convener such as C-Path will enable our community to collaborate better, share data, and accelerate the development of much-needed treatments. We are grateful to C-Path for their partnership throughout many months of putting this together and look forward to the next steps and achievements as this task force takes shape.”

- Sophia Zilber, Cure MITO Foundation board member

To read the full press release please visit https://c-path.org/c-path-to-lead-new-task-force-aimed

Thank you again to this community, from the PDCD patients and the people that love them and their parents. We hope to continue to earn your steadfast support in 2024.

Yours in Hope,

Frances and Jon

Parents to Kai and Violet, Founders of Hope for PDCD 🧬